The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters ...

Nasal spray tech facilitates the delivery of proteins, small-molecule drugs and peptides. Credit: 1777177/Shutterstock. The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The FDA ap­proved a new nasal spray for mi­graines that was de­vel­oped by Sat­suma Phar­ma­ceu­ti­cals.

Chairman/CEO, Parabilis Medicines; Former EVP R&D, Johnson & Johnson ...

Diazepam nasal spray (Valtoco) is approved for short-term treatment of seizure clusters, now in patients aged 2 years and older. On April 16, 2025, the FDA approved an expanded indication for diazepam ...

Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain by 2 hours post-treatment in 34.2% of migraine attacks. The FDA has approved ...